Name (Synonyms) | Correlation | |
---|---|---|
drug447 | Ivermectin Wiki | 0.58 |
drug386 | Hydroxychloroquine Sulfate Regular dose Wiki | 0.58 |
drug549 | Nitazoxanide Wiki | 0.58 |
drug385 | Hydroxychloroquine Sulfate Loading Dose Wiki | 0.58 |
drug546 | Niclosamide Wiki | 0.41 |
drug583 | Other drugs Wiki | 0.41 |
drug729 | Saliva Wiki | 0.41 |
drug271 | Duodenal biopsy Wiki | 0.41 |
drug600 | Patient management suffering of coronavirus infection Wiki | 0.41 |
drug266 | Docetaxel Wiki | 0.41 |
drug234 | Coping strategies video Wiki | 0.41 |
drug111 | Berzosertib Wiki | 0.41 |
drug153 | COVID-19 barrier box Wiki | 0.41 |
drug176 | Carboplatin Wiki | 0.41 |
drug456 | Laboratory Biomarker Analysis Wiki | 0.41 |
drug304 | Favipiravir Wiki | 0.17 |
drug627 | Placebo oral tablet Wiki | 0.09 |
drug616 | Placebo Wiki | 0.08 |
Name (Synonyms) | Correlation | |
---|---|---|
D000077062 | Burnout, Psychological NIH | 0.58 |
D011471 | Prostatic Neoplasms NIH | 0.41 |
D017250 | Caliciviridae Infections NIH | 0.41 |
D002277 | Carcinoma NIH | 0.29 |
D058070 | Asymptomatic Diseases NIH | 0.29 |
D013315 | Stress, Psychological NIH | 0.24 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D003141 | Communicable Diseases NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.05 |
D007239 | Infection NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012125 | Prostate cancer HPO | 0.41 |
HP:0030731 | Carcinoma HPO | 0.41 |
There are 6 clinical trials
COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.
Description: the estimated number of patients with decreased viral load
Measure: Number of patients with decreased viral load Time: 6 monthsTo create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR negative status Time: 6-7 daysDescription: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Time to onset of fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute).
Measure: Development of Symptoms Time: 7 daysDescription: Drug related adverse events as determined by data safety and monitoring board (DSMB)
Measure: Adverse events Time: 7 daysThe primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.
Description: Symptomatic illness is defined as COVID infection guidelines and confirmed with anti-COVID antibodies that will be done on serum collect at the final visit. Symptoms include fever, chills, muscle pain, cough, shortness of breath, and diarrhea.
Measure: Number of symptomatic illness in at risk healthcare workers Time: Up to 3 monthsDescription: Diagnosis is based on symptoms of COVID-19 and confirmatory anti-COVID antibodies and when available, COVID-19 PCR.
Measure: Number of healthcare workers with symptomatic COVID infections Time: Up to 3 monthsDescription: Severe illness includes worsening of symptoms.
Measure: Number of severe illness in at risk healthcare workers Time: Up to 3 monthsDescription: Confirmation with polymerase chain reaction (PCR) when available.
Measure: Number of sero-conversions in at risk healthcare workers Time: Up to 3 monthsDescription: Adverse events that are NCI-CTCAE Grade 3 or higher will be counted.
Measure: Percentage of patients with adverse events Grade 3 or higher Time: Up to 3 monthsDescription: GI intolerance to chloroquine will be documented and recorded.
Measure: Percentage of patients with GI intolerance Time: Up to 3 monthsTo treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR result Time: 6th and 7th dayDescription: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Death
Measure: Mortality Time: 30 daysEfficacy of Ivermectin and Nitazoxanide in COVID-19 treatment
Description: Number of patients with virological cure
Measure: Number of patients with virological cure Time: 6 monthsChloroquine in COVID-19 treatment
Description: the number of patients with virological cure
Measure: Number of patients with virological cure Time: 6 months